Results 1 to 10 of about 7,007,196 (291)

An overview of recent advances in opioid agonist treatment (OAT) [PDF]

Irish Journal of Psychological Medicine, 2021
M. McNicholas, M. Scully, E. Keenan
openaire   +2 more sources

Delta-opioid receptor endocytosis in spinal cord after dermenkephalin activation

BMC Neuroscience, 2000
Background The delta(δ)-opioid receptors belong to the G protein-coupled receptors and in vitro studies have shown that δ-opioid receptors undergo an internalization process in response to agonist stimulation.
Gastard Myriam
doaj   +1 more source

A qualitative study of experiences with physical activity among people receiving opioid agonist therapy

Substance Abuse Treatment, Prevention, and Policy
Background Physical or mental health comorbidities are common among people with substance use disorders undergoing opioid agonist therapy. As both a preventive and treatment strategy, exercise offers various health benefits for several conditions ...
Einar Furulund, Siv-Elin Leirvåg Carlsen, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Lars T Fadnes, Torgeir Gilje Lid   +5 more
doaj   +1 more source

Long-term agonist and antagonist therapy for adolescent opioid dependence: A description of two cases

Indian Journal of Psychological Medicine, 2014
Adolescents constitute only a small percentage of treatment seekers in drug dependence treatment settings. Little research evidence is available for pharmacological treatment of adolescent opioid dependence and no prior case report is available from ...
Rajeev Ranjan, Raman Deep Pattanayak, Anju Dhawan   +2 more
doaj   +1 more source

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder

Addictive Behaviors Reports, 2018
Introduction: People with chronic opioid use disorder often present to treatment with individual and structural vulnerabilities and remain at risk of reporting adverse health outcomes.
Heather Palis, Kirsten Marchand, Mohammad Karamouzian, Scott MacDonald, Scott Harrison, Daphne Guh, Kurt Lock, Suzanne Brissette, Aslam H. Anis, Michael Krausz, David C. Marsh, Martin T. Schechter, Eugenia Oviedo-Joekes   +12 more
doaj   +1 more source

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

Substance Abuse and Rehabilitation, 2011
Paolo Mannelli, Kathleen S Peindl, Li-Tzy WuDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USAPurpose: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that ...
Peindl K, Mannelli P, Wu LT
doaj  

Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework

Addiction Science & Clinical Practice
Background Few studies have systematically examined the barriers and facilitators to buprenorphine uptake, despite increasing opioid-related harms and guideline recommendations for use.
Pamela Leece, Triti Khorasheh, Suzanne Zerger, Kim Corace, Lara Nixon, Carol Strike, Ahmed M. Bayomi, Elisabeth Marks, Melissa Holowaty, Frank Crichlow, Sheena Taha, Sharon E. Straus   +11 more
doaj   +1 more source

Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt

JAMA Network Open
ImportanceAt the onset of the COVID-19 pandemic, the government of British Columbia, Canada, released clinical guidance to support physicians and nurse practitioners in prescribing pharmaceutical alternatives to the toxic drug supply. These alternatives included opioids and other medications under the risk mitigation guidance (RMG), a limited form of ...
Min, Jeong Eun, Guerra-Alejos, Brenda Carolina, Yan, Ruyu, Palis, Heather, Barker, Brittany, Urbanoski, Karen, Pauly, Bernie, Slaunwhite, Amanda, Bach, Paxton, Ranger, Corey, Heaslip, Ashley, Nosyk, Bohdan   +11 more
openaire   +2 more sources

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

Substance Abuse Treatment, Prevention, and Policy
Background Across different types of oral Opioid Agonist Treatment for people with Opioid Use Disorder, receiving a dose that meets their needs is associated with better outcomes. Evidence also shows patients are more likely to receive an “adequate dose”
Scott Beaumont, Tianna Magel, Scott MacDonald, Scott Harrison, Martin Schechter, Eugenia Oviedo-Joekes   +5 more
doaj   +1 more source

Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study

PLoS Medicine, 2022
Background The overdose crisis in North America has prompted system-level efforts to restrict opioid prescribing for chronic pain. However, little is known about how discontinuing or tapering prescribed opioids for chronic pain shapes overdose risk ...
Mary Clare Kennedy, Alexis Crabtree, Seonaid Nolan, Wing Yin Mok, Zishan Cui, Mei Chong, Amanda Slaunwhite, Lianping Ti   +7 more
doaj